<DOC>
	<DOCNO>NCT00099268</DOCNO>
	<brief_summary>The CELC200A2401 study design order evaluate hypothesis administer combination carbidopa/levodopa/entacapone time levodopa therapy initiate result decrease risk development motor complication patient Parkinson 's disease .</brief_summary>
	<brief_title>Efficacy Safety Carbidopa/Levodopa/Entacapone Patients With Parkinson 's Disease Requiring Initiation Levodopa Therapy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Clinical diagnosis idiopathic Parkinson 's disease Diagnosis Parkinson 's disease 5 year History , sign , symptom atypical secondary parkinsonism Presence baseline drugrelated wearingoff symptom , dyskinesia motor complication Levodopa exposure 30 day anytime within 8 week prior visit 1 Other inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Parkinson 's disease , levodopa therapy , dyskinesia</keyword>
</DOC>